Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes

PURPOSE: Ruxolitinib is an oral Janus kinase (JAK) 1/JAK2 inhibitor approved in the US for the treatment of intermediate-or high-risk myelofibrosis (MF). Because thrombopoietin and erythropoietin signal through JAK2, dose-dependent cytopenias are expected with treatment. In the COMFORT-I (COntrolled...

Descripción completa

Detalles Bibliográficos
Autores principales: Verstovsek, Srdan, Gotlib, Jason, Gupta, Vikas, Atallah, Ehab, Mascarenhas, John, Quintas-Cardama, Alfonso, Sun, William, Sarlis, Nicholas J, Sandor, Victor, Levy, Richard S, Kantarjian, Hagop M, Mesa, Ruben A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869911/
https://www.ncbi.nlm.nih.gov/pubmed/24368888
http://dx.doi.org/10.2147/OTT.S53348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869911/
https://www.ncbi.nlm.nih.gov/pubmed/24368888
http://dx.doi.org/10.2147/OTT.S53348

Ejemplares similares